4.6 Article

Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer?

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer A Randomized Clinical Trial

Jiren Yu et al.

Summary: Perioperative chemotherapy is a potential treatment for locally advanced gastric cancer, but the optimal regimen remains unknown. This study compared the safety and efficacy of S-1 plus oxaliplatin (SOX) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX) as perioperative chemotherapy regimens for locally advanced gastric cancer patients. The results showed that SOX was noninferior to FOLFOX and could be recommended as an alternative treatment in Asia.

JAMA NETWORK OPEN (2022)

Article Oncology

Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer

Justin A. Drake et al.

Summary: This study demonstrated that only a minority of patients who received preoperative chemotherapy followed by gastric cancer surgery also received postoperative chemotherapy, and the impact on overall survival was limited. Postoperative chemotherapy may benefit patients with N1 disease, but no significant survival benefit was observed for other subgroups. Future trials should focus on determining which patients will benefit from postoperative chemotherapy.

ANNALS OF SURGICAL ONCOLOGY (2021)

Article Oncology

Modified ypTNM Staging Classification for Gastric Cancer after Neoadjuvant Therapy: AMulti-InstitutionalStudy

Qing Zhong et al.

Summary: A modified ypTNM staging was developed and validated through multi-center data, showing superior prognostic accuracy and predictive power for assessing the prognosis of patients with gastric cancer after neoadjuvant therapy compared to the AJCC 8th edition ypTNM staging.

ONCOLOGIST (2021)

Article Oncology

Current treatment and recent progress in gastric cancer

Smita S. Joshi et al.

Summary: Gastric cancer is a common cause of cancer death worldwide, with treatment options including systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy. Classification and biomarkers for gastric cancer help in personalized therapy and identifying populations most likely to benefit from immunotherapy and targeted therapy.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Article Oncology

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Yoon-Koo Kang et al.

Summary: The PRODIGY study demonstrated that neoadjuvant DOS chemotherapy as part of perioperative chemotherapy is effective and well tolerated in Korean patients with LAGC.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

Feng-Hua Wang et al.

Summary: Gastric cancer patients from Eastern and Western countries exhibit different characteristics, and the Chinese Society of Clinical Oncology has developed guidelines that take into account regional differences and aim to provide personalized recommendations. The 2021 guidelines cover various aspects of gastric cancer diagnosis and treatment, integrating research data from both China and overseas to offer more relevant recommendations.

CANCER COMMUNICATIONS (2021)

Article Medicine, General & Internal

The Effectiveness of Postoperative Chemotherapy on pT1bN0 and pT2N0 Gastric Cancer Patients with Risk Factors: An International Dual-Center Analysis

Kun Yang et al.

Summary: This study found that age is an independent prognostic factor in pT1bN0 and pT2N0 gastric cancer patients. Postoperative chemotherapy may offer survival benefits to pT2N0 patients with more than two risk factors.

YONSEI MEDICAL JOURNAL (2021)

Review Oncology

Global chemotherapy development for gastric cancer

Kazuto Harada et al.

GASTRIC CANCER (2017)

Review Oncology

Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?

Sing Yu Moorcraft et al.

GASTRIC CANCER (2015)

Article Medicine, General & Internal

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

P. van Hagen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

David Cunningham et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)